These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 9174799)
21. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO]. Simoons ML; Casparie AF Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223 [TBL] [Abstract][Full Text] [Related]
22. Lovastatin to prevent acute coronary events with average cholesterol levels. MacFarlane LL; Carek PJ J Fam Pract; 1998 Aug; 47(2):91-2. PubMed ID: 9722787 [No Abstract] [Full Text] [Related]
23. Hypercholesterolemia: a reversible risk factor for coronary heart disease. Mishkel MA CMAJ; 1989 Feb; 140(4):419. PubMed ID: 2644008 [No Abstract] [Full Text] [Related]
24. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Gotto AM Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414 [TBL] [Abstract][Full Text] [Related]
25. A need to redefine the consensus on the use of statins in coronary heart disease prevention. Fruchart JC Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008 [No Abstract] [Full Text] [Related]
26. Guidelines for cholesterol management: recommendations of the National Cholesterol Education Program's Adult Treatment Panel II. Grundy SM Heart Dis Stroke; 1994; 3(3):123-7. PubMed ID: 8044423 [No Abstract] [Full Text] [Related]
27. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Johannesson M Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815 [TBL] [Abstract][Full Text] [Related]
28. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis]. Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081 [No Abstract] [Full Text] [Related]
29. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease? Colquhoun DM Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884 [TBL] [Abstract][Full Text] [Related]
30. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Wright DJ; Grayson AD; Jackson M; Dainty C Int J Clin Pract; 2003; 57(6):488-91. PubMed ID: 12918888 [TBL] [Abstract][Full Text] [Related]
31. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease. Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017 [TBL] [Abstract][Full Text] [Related]